BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $110.00

BridgeBio Pharma (NASDAQ:BBIO) had its price objective raised by research analysts at TD Cowen from $95.00 to $110.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. TD Cowen’s price objective points to a potential upside of 31.09% from the company’s current price.

Other equities analysts have also issued research reports about the stock. Citigroup lifted their price target on shares of BridgeBio Pharma from $82.00 to $93.00 and gave the company a “neutral” rating in a research report on Thursday, July 16th. Canaccord Genuity Group initiated coverage on BridgeBio Pharma in a research report on Wednesday, June 3rd. They issued a “buy” rating and a $104.00 target price for the company. Morgan Stanley raised their target price on BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research report on Thursday, May 28th. Wells Fargo & Company raised their price objective on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday. Finally, Mizuho reduced their target price on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating on the stock in a research report on Tuesday, June 16th. Nineteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $99.28.

BridgeBio Pharma Trading Down 0.9%

BBIO stock traded down $0.76 during mid-day trading on Tuesday, hitting $83.92. The stock had a trading volume of 990,910 shares, compared to its average volume of 2,991,225. The company has a fifty day moving average of $76.07 and a 200 day moving average of $73.03. BridgeBio Pharma has a 1-year low of $46.81 and a 1-year high of $93.42. The stock has a market capitalization of $16.40 billion, a price-to-earnings ratio of -22.45 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.20). The company had revenue of $243.68 million for the quarter, compared to analysts’ expectations of $220.91 million. The business’s quarterly revenue was up 120.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. As a group, sell-side analysts expect that BridgeBio Pharma will post -2.31 earnings per share for the current fiscal year.

Insider Transactions at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $67.46, for a total value of $2,698,400.00. Following the completion of the transaction, the chief executive officer owned 535,686 shares of the company’s stock, valued at approximately $36,137,377.56. This trade represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Randal W. Scott sold 10,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $67.15, for a total transaction of $671,500.00. Following the transaction, the director owned 11,589 shares of the company’s stock, valued at approximately $778,201.35. This represents a 46.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 392,117 shares of company stock worth $29,934,700. Company insiders own 14.23% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its stake in BridgeBio Pharma by 19.8% in the first quarter. Janus Henderson Group PLC now owns 13,179,013 shares of the company’s stock valued at $978,608,000 after buying an additional 2,178,556 shares during the period. Farallon Capital Management LLC increased its holdings in shares of BridgeBio Pharma by 9.8% during the fourth quarter. Farallon Capital Management LLC now owns 8,998,463 shares of the company’s stock worth $688,292,000 after purchasing an additional 806,463 shares during the period. Invesco Ltd. raised its holdings in BridgeBio Pharma by 23.0% in the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after acquiring an additional 902,648 shares in the last quarter. Geode Capital Management LLC increased its holdings in BridgeBio Pharma by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 4,412,523 shares of the company’s stock valued at $344,689,000 after buying an additional 502,582 shares during the period. Finally, Price T Rowe Associates Inc. MD increased its stake in shares of BridgeBio Pharma by 144.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock valued at $292,862,000 after purchasing an additional 2,261,181 shares during the last quarter. 99.85% of the stock is currently owned by institutional investors and hedge funds.

More BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analysts raise targets: Piper Sandler increased its price target from $111 to $115 and maintained an “overweight” rating. Wells Fargo also raised its target, from $98 to $102, while keeping an “overweight” rating. The revisions imply substantial potential upside and reflect continued confidence in BridgeBio’s development pipeline. Benzinga analyst price-target updates
• Positive Sentiment: Pipeline catalysts could drive sentiment: BridgeBio is listed among biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical-trial readouts. Positive data or approvals could provide important valuation catalysts for BBIO. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Neutral Sentiment: Revenue growth was strong: Second-quarter revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% from the prior year. The improvement suggests commercial and partnered-product activity is expanding, although investors remain focused on the company’s path toward profitability. BridgeBio Pharma Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Quarterly loss exceeded expectations: BridgeBio reported a second-quarter loss of $0.78 per share, wider than the $0.58 analyst consensus, despite improving from a $0.95 loss per share a year earlier. The earnings miss may limit the stock’s near-term upside and reinforce concerns about ongoing cash needs and operating costs. BridgeBio Pharma Q2 Earnings Results and Conference Call

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.